A Phase 1, single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of a SC infusion of Crenezumab or placebo in Healthy Subjects
Latest Information Update: 12 Aug 2021
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 12 Aug 2021 New trial record
- 04 Aug 2021 Results published in the Clinical Pharmacology and Therapeutics